Cargando…

Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938635/ https://www.ncbi.nlm.nih.gov/pubmed/36819977 http://dx.doi.org/10.1093/immadv/ltad002

Ejemplares similares

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
por: Schwartz, Stephanie, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors
por: Xu, Siyan, et al.
Publicado: (2023)

Correction: Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation
por: Li, Peiyao, et al.
Publicado: (2023)

Correction: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
por: Cao, Yang, et al.
Publicado: (2016)

Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Publicado: (2023)

Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
Publicado: (2021)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

Correction to: Inhibition of T cell immunoglobulin and mucin-1 (TIM-1) protects against cerebral ischemia-reperfusion injury
por: Zheng, Yueying, et al.
Publicado: (2019)

Correction to: Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
por: Hao, Zhaonian, et al.
Publicado: (2022)

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Publicado: (2020)

Correction: Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
por: Huang, Xiaoyuan, et al.
Publicado: (2021)

Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
Publicado: (2020)

Correction: Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Publicado: (2023)

The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2016)

Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
por: Homayouni, Vida, et al.
Publicado: (2016)

Correction: Drosophila TIM Binds Importin α1, and Acts as an Adapter to Transport PER to the Nucleus
Publicado: (2015)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Author Correction: The immuno-oncological challenge of COVID-19
por: Derosa, Lisa, et al.
Publicado: (2022)

Correction to: A proteome-wide immuno-mass spectrometric identification of serum autoantibodies
por: Music, Milena, et al.
Publicado: (2019)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
por: Du, Wenwen, et al.
Publicado: (2017)

Tim-3 finds its place in the cancer immunotherapy landscape
por: Acharya, Nandini, et al.
Publicado: (2020)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction: Identification and Characterization of ZEL-H16 as a Novel Agonist of the Histamine H(3) Receptor
por: Shi, Ying, et al.
Publicado: (2012)

Correction: Observations of Immuno-Gold Conjugates on Influenza Viruses Using Waveguide-Mode Sensors
por: Gopinath, Subash C. B., et al.
Publicado: (2013)

Correction: A20 (Tnfaip3) Deficiency in Myeloid Cells Protects against Influenza A Virus Infection
por: Maelfait, Jonathan, et al.
Publicado: (2012)

Author Correction: A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
por: Candini, Olivia, et al.
Publicado: (2020)

Author Correction: Histone acetyltransferease p300 modulates TIM4 expression in dendritic cells
por: Yang, Bo, et al.
Publicado: (2021)

Correction: Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study
por: McKay, James, et al.
Publicado: (2017)

Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells
por: Silva, Isabel Gonçalves, et al.
Publicado: (2015)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
por: Wu, Zhengwei, et al.
Publicado: (2022)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

Phosphatidylserine binding directly regulates TIM-3 function
por: Smith, Courtney M., et al.
Publicado: (2021)

Correction: Characterization of the Murine Myeloid Precursor Cell Line MuMac-E8
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lrkd11k7jfpc0fsbgk6h1b7qep